Lilly: Can the Zepbound® (tirzepatide) vial be split into smaller doses?
National Library of Medicine: Tirzepatide
Important Medical Information and Disclaimers
MEDICAL DISCLAIMER: This information is for educational purposes only and is not intended as medical advice. Tirzepatide is available as FDA‑approved prescription medications—Mounjaro® (for type 2 diabetes) and Zepbound® (for chronic weight management and obstructive sleep apnea in adults with obesity). Always consult a qualified healthcare provider before starting any treatment.
INDIVIDUAL RESULTS VARY: Outcomes with tirzepatide vary significantly between individuals. Results may be influenced by treatment adherence, lifestyle modifications, individual metabolism, growth and development (in adolescents), underlying health conditions, and emotional wellbeing.
IMPORTANT SAFETY INFORMATION:
-
Common side effects: nausea, vomiting, diarrhea, constipation, abdominal discomfort, decreased appetite, and injection-site reactions.
-
Serious side effects: have included pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia, and severe allergic or injection-site reactions.
-
Thyroid considerations: Animal studies demonstrated thyroid C‑cell tumors; the relevance to humans is unknown. Zepbound/Mounjaro is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
COMPOUNDED VERSIONS WARNING: The FDA has issued alerts regarding compounded tirzepatide, warning that these custom formulations may lack the safety, consistency, and efficacy of FDA-approved medications.
FDA ADVERSE EVENT REPORTING: You are encouraged to report negative side effects of prescription medications. Visit FDA MedWatch at www.fda.gov/medwatch or call 1‑800‑FDA‑1088.